[{"indications": "Indications\u00a0see notes above; inflammatory bowel\r\ndisease (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB); ankylosing spondylitis, psoriatic\r\narthritis, rheumatoid arthritis (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB)", "name": "INFLIXIMAB - PREPARATIONS FOR ECZEMA AND PSORIASIS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "Cytokine modulators", "INFLIXIMAB"], "cautions": "Cautions\u00a0section 10.1.3; monitor for non-melanoma skin cancer before and during treatment", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201661.htm", "doses": ["By intravenous infusion, plaque psoriasis, adult over 18 years, 5\u00a0mg/kg, repeated 2 weeks and\r\n6 weeks after initial infusion, then every 8 weeks; discontinue if\r\nno response within 14 weeks of initial infusion"], "pregnancy": "Pregnancy\u00a0section\r\n10.1.3"}, {"indications": "Indications\u00a0see notes above; inflammatory bowel\r\ndisease (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB); ankylosing spondylitis, psoriatic\r\narthritis, rheumatoid arthritis (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB)", "name": "INFLIXIMAB - DRUGS AFFECTING THE IMMUNE RESPONSE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "Cytokine modulators"], "cautions": "Cautions\u00a0section 10.1.3; monitor for non-melanoma skin cancer before and during treatment", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201653.htm", "doses": ["By intravenous infusion, plaque psoriasis, adult over 18 years, 5\u00a0mg/kg, repeated 2 weeks and\r\n6 weeks after initial infusion, then every 8 weeks; discontinue if\r\nno response within 14 weeks of initial infusion"], "pregnancy": "Pregnancy\u00a0section\r\n10.1.3"}, {"indications": "Indications\u00a0see notes above; inflammatory bowel\r\ndisease (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB); ankylosing spondylitis, psoriatic\r\narthritis, rheumatoid arthritis (%s\n(From INFLIXIMAB: British National Formulary)\nINFLIXIMAB)", "name": "INFLIXIMAB", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "13 Skin", "13.5 Preparations for eczema and psoriasis", "13.5.3 Drugs affecting the immune response", "Cytokine modulators", "INFLIXIMAB"], "cautions": "Cautions\u00a0section 10.1.3; monitor for non-melanoma skin cancer before and during treatment", "side-effects": "Side-effects\u00a0section 10.1.3", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201661.htm", "doses": ["By intravenous infusion, plaque psoriasis, adult over 18 years, 5\u00a0mg/kg, repeated 2 weeks and\r\n6 weeks after initial infusion, then every 8 weeks; discontinue if\r\nno response within 14 weeks of initial infusion"], "pregnancy": "Pregnancy\u00a0section\r\n10.1.3"}, {"indications": "Indications\u00a0see under Cytokine Modulators above; inflammatory bowel\r\ndisease (section 1.5.3); psoriasis (section 13.5.3)", "name": "INFLIXIMAB - DRUGS THAT SUPPRESS THE RHEUMATIC DISEASE PROCESS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "10 Musculoskeletal and joint diseases", "10.1 Drugs used in rheumatic diseases and gout", "10.1.3 Drugs that suppress the rheumatic disease process", "Cytokine modulators", "INFLIXIMAB"], "cautions": "Cautions\u00a0predisposition to infection; monitor for infection before, during, and for 6 months after treatment (see also Tuberculosis below); discontinue if new serious\r\ninfection develops; hepatitis B virus\u2014monitor\r\nfor active infection; mild heart failure\r\n(discontinue if symptoms develop or worsen); demyelinating disorders (risk of exacerbation); history or development of malignancy; history of prolonged immunosuppressant or PUVA treatment in patients\r\nwith psoriasis; interactions: Appendix\r\n1 (infliximab) Tuberculosis\u00a0Patients should be evaluated for\r\ntuberculosis before treatment. Active tuberculosis should\r\nbe treated with standard treatment (section 5.1.9) for at least 2 months before\r\nstarting infliximab. Patients who have previously received\r\nadequate treatment for tuberculosis can start infliximab but should\r\nbe monitored every 3 months for possible recurrence. In patients without active tuberculosis but who were previously not\r\ntreated adequately, chemoprophylaxis should ideally be completed before\r\nstarting infliximab. In patients at high\r\nrisk of tuberculosis who cannot be assessed by tuberculin skin test,\r\nchemoprophylaxis can be given concurrently with infliximab. Patients should be advised to seek medical attention\r\nif symptoms suggestive of tuberculosis (e.g. persistent cough, weight\r\nloss, and fever) developBlood disorders\u00a0Patients should be\r\nadvised to seek medical attention if symptoms suggestive of blood\r\ndisorders (such as fever, sore throat, bruising, or bleeding) developHypersensitivity reactions\u00a0Hypersensitivity reactions\r\n(including fever, chest pain, hypotension, hypertension, dyspnoea,\r\ntransient visual loss, pruritus, urticaria, serum sickness-like reactions,\r\nangioedema, anaphylaxis) reported during or within 1\u20132 hours after\r\ninfusion (risk greatest during first or second infusion or in patients\r\nwho discontinue other immunosuppressants). All patients should be observed carefully for 1\u20132 hours after infusion\r\nand resuscitation equipment should be available for immediate use.\r\nProphylactic antipyretics, antihistamines, or hydrocortisone may be administered. Monitor for symptoms of delayed hypersensitivity\r\nif readministered after a prolonged period. Patients\r\nshould be advised to keep Alert card with them at all times and seek medical advice if symptoms of delayed hypersensitivity\r\ndevelop", "side-effects": "Side-effects\u00a0see under Cytokine Modulators and under Cautions above; also constipation, diarrhoea, dyspepsia,\r\ngastro-intestinal haemorrhage, gastro-oesophageal reflux, flushing,\r\nhypotension, hypertension, palpitation, tachycardia, sleep disturbances,\r\ndizziness, paraesthesia, hypoaesthesia, arthralgia, myalgia, epistaxis,\r\nalopecia, rash, ecchymosis, hyperhydrosis, new onset or worsening\r\npsoriasis, dry skin; less commonly hepatitis, cholecystitis,\r\nintestinal perforation, pancreatitis, heart failure, arrhythmia, bradycardia,\r\nsyncope, peripheral ischaemia, pleurisy, pulmonary oedema, amnesia,\r\nagitation, confusion, nervousness, neuropathy, seizures, vaginitis,\r\neye disorders, bullous eruption, cheilitis, seborrhoea, impaired healing,\r\nrosacea, hyperkeratosis, abnormal skin pigmentation; rarely pericardial effusion, vasospasm, interstitial lung disease, leukaemia,\r\nlymphoma, demyelinating disorders, Stevens-Johnson syndrome, toxic\r\nepidermal necrolysis; also reported hepatic failure", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128235.htm", "doses": ["By intravenous infusion, rheumatoid\r\narthritis (in combination with methotrexate), adult over 18 years, 3\u00a0mg/kg, repeated 2 weeks and 6 weeks after initial\r\ninfusion, then every 8 weeks; if response inadequate after 12 weeks,\r\ndose may be increased in steps of 1.5\u00a0mg/kg every 8 weeks, up to max.\r\n7.5\u00a0mg/kg every 8 weeks; alternatively, 3\u00a0mg/kg may be given every\r\n4 weeks; discontinue if no response by 12 weeks of initial infusion\r\nor after dose adjustment", "Ankylosing spondylitis, adult over 18 years, 5\u00a0mg/kg, repeated 2 weeks and 6 weeks after initial\r\ninfusion, then every 6\u20138 weeks; discontinue if no response by 6 weeks\r\nof initial infusion", "Psoriatic arthritis (in combination with methotrexate), adult over 18 years, 5\u00a0mg/kg, repeated\r\n2 weeks and 6 weeks after initial infusion, then every 8 weeks"], "pregnancy": "Pregnancy\u00a0use only if essential; manufacturer advises adequate\r\ncontraception during and for at least 6 months after last dose"}, {"indications": "Indications\u00a0see under Inflammatory Bowel Disease; ankylosing spondylitis,\r\nrheumatoid arthritis (section 10.1.3); psoriasis (section 13.5.3)", "name": "INFLIXIMAB - CHRONIC BOWEL DISORDERS", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.3 Drugs affecting the immune response", "Cytokine modulators"], "cautions": "Cautions\u00a0see section 10.1.3;\r\nalso history of dysplasia or colon carcinomaHypersensitivity reactions\u00a0Risk of delayed hypersensitivity if drug-free interval exceeds\r\n16 weeks", "side-effects": "Side-effects\u00a0see section 10.1.3;\r\nalso hepatosplenic T-cell lymphoma", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128211.htm", "doses": ["By intravenous infusion, severe active\r\nCrohn\u2019s disease, adult over 18 years,\r\ninitially 5\u00a0mg/kg, then 5\u00a0mg/kg 2 weeks after initial dose; then if\r\nthe condition has responded, maintenance 5\u00a0mg/kg 6 weeks after initial\r\ndose, then 5\u00a0mg/kg every 8 weeks; child 6\u201318 years, initially 5\u00a0mg/kg, then 5\u00a0mg/kg 2 weeks and 6 weeks\r\nafter initial dose, then 5\u00a0mg/kg every 8 weeks; interval between maintenance\r\ndoses adjusted according to response; discontinue if no response within\r\n10 weeks of initial dose", "Fistulating Crohn\u2019s disease, adult over 18 years, initially 5\u00a0mg/kg, then 5\u00a0mg/kg 2 weeks and 6 weeks\r\nafter initial dose, then if condition has responded, consult product\r\nliterature for guidance on further doses; child under 18 years, see BNF for Children", "Severe active ulcerative colitis, adult over 18 years, initially 5\u00a0mg/kg, then 5\u00a0mg/kg 2 weeks and 6 weeks\r\nafter initial dose, then 5\u00a0mg/kg every 8 weeks; discontinue if no\r\nresponse 14 weeks after initial dose"], "pregnancy": "Pregnancy\u00a0section 10.1.3"}]